A study published in Clinical Therapeutics found potential cost savings associated with the use of the IBS diagnostic blood panel IBSchek.
The researchers utilized a cost-minimization decision tree model, a budget impact analysis and physician surveys to compare the economic values.
Here are five points:
1. A budget impact analysis estimated that when the cost savings are amortized over one million lives, IBSchek will save healthcare payers more than $3.5 million annually.
2. A cost-minimization decision tree model predicted an estimated a $509 cost saving with use of IBSchek versus the exclusionary diagnostic pathway, which is the current standard of care.
3. Additionally, the exclusionary diagnostic pathway used in this study did not consider repeated investigations, the potential for more invasive studies stemming from false-positive results of the investigations or the cost of pathology assessments.
4. Salem, Mass.-based Commonwealth Laboratories developed IBSchek.
5. Commonwealth Laboratories is an independent diagnostic laboratory offering specialized diagnostic tests to aid in the diagnosis of a variety of functional gastrointestinal disorders.